$16.99
1.07% yesterday
Nasdaq, Dec 24, 07:00 pm CET
ISIN
US24823R1059
Symbol
DNLI

Denali Therapeutics Inc. Stock price

$16.99
-1.94 10.25% 1M
+2.59 17.99% 6M
-3.39 16.63% YTD
-3.93 18.79% 1Y
-10.88 39.04% 3Y
-68.88 80.21% 5Y
-4.46 20.79% 10Y
-4.46 20.79% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.18 1.07%
ISIN
US24823R1059
Symbol
DNLI
Industry

New AI Insights on Denali Therapeutics Inc. Insights AI Insights on Denali Therapeutics Inc.

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$2.7b
Enterprise Value
$1.8b
Net debt
positive
Cash
$848.2m
Shares outstanding
146.6m
Valuation (TTM | estimate)
P/E
- | negative
P/S
- | 2,427.4
EV/Sales
- | 1,656.4
EV/FCF
negative
P/B
2.9
Financial Health
Equity Ratio
89.5%
Return on Equity
-34.4%
ROCE
-
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
- | $1.1m
EBITDA
- | $-543.6m
EBIT
- | $-565.3m
Net Income
- | $-440.9m
Free Cash Flow
$-411.0m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -10.3%
EBIT
- | -12.6%
Net Income
- | -4.3%
Free Cash Flow
-9.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -49,738.3%
EBIT
-
Net
- | -40,340.3%
Free Cash Flow
-
More
EPS
-
FCF per Share
$-2.8
Short interest
9.9%
Employees
422
Rev per Employee
$0.0
Show more

Is Denali Therapeutics Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Denali Therapeutics Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

24 Analysts have issued a Denali Therapeutics Inc. forecast:

23x Buy
96%
1x Hold
4%

Analyst Opinions

24 Analysts have issued a Denali Therapeutics Inc. forecast:

Buy
96%
Hold
4%

Financial data from Denali Therapeutics Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 116 116
16% 16%
-
- Research and Development Expense - -
-
-
-522 -522
7% 7%
-
- Depreciation and Amortization 12 12
41% 41%
-
EBIT (Operating Income) EBIT -534 -534
8% 8%
-
Net Profit -479 -479
14% 14%
-

In millions USD.

Don't miss a Thing! We will send you all news about Denali Therapeutics Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Denali Therapeutics Inc. Stock News

Neutral
The Motley Fool
15 days ago
Wednesday brought gains for major stock benchmarks. The Federal Reserve cut interest rates but signaled a slowing in expected future reductions.
Positive
Seeking Alpha
15 days ago
Denali Therapeutics Inc. is maintained at a Strong Buy rating, driven by progress in its MPS II [Hunter Syndrome] program with tividenofusp alfa. Despite discontinuing ALS efforts, DNLI's BLA for tividenofusp alfa is under FDA Priority Review under Accelerated Approval pathway, with PDUFA date extended to April 5, 2026. Company's ETV platform enables expansion into additional lysosomal storage ...
Neutral
GlobeNewsWire
15 days ago
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of its underwritten public offering of 9,142,857 shares of its common stock at a price to the public of $17.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 2,285,714 shares of common stock at a price of $17.49 per pre-...
More Denali Therapeutics Inc. News

Company Profile

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Head office United States
CEO Ryan Watts
Employees 422
Founded 2013
Website www.denalitherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today